头孢哌酮／舒巴坦对临床分离菌的药物敏感性分析  

Analysis of antimicrobial susceptibility of cefoperazone/sulbactam to clinical isolated bacteria

作　　者：曲芬[1] 贾天野[1] 袁媛[1] 张树永[1] 陈素明[1] 庞君丽[1] 徐璇[1] 张敬霞[1] 鲍春梅[1] 李进[2] 

机构地区：[1]解放军第三0二医院临床检验医学中心,北京100039 [2]解放军第三0二医院医务部,北京100039

出　　处：《中国抗生素杂志》2017年第7期570-574,共5页Chinese Journal of Antibiotics

摘　　要：目的探讨头孢哌酮/舒巴坦对临床分离菌特别是MDR菌的抗菌活性。方法采用纸片扩散法测定头孢哌酮/舒巴坦对临床分离细菌的药物敏感性,结果判断按CLSI的头孢哌酮标准,并与其他抗生素的耐药率比较。结果头孢哌酮/舒巴坦9年间的耐药率增长不明显,对常见临床分离革兰阴性菌的耐药率为10.8%,明显低于除亚胺培南、阿米卡星外的抗生素(P=0),对临床治疗棘手MDR的鲍曼不动杆菌、铜绿假单胞菌、产超广谱β-内酰胺酶菌株和产碳青霉烯酶肠杆菌的耐药率分别为41.3%、13.5%、14%和59.3%,均低于三代头孢菌素、左氧氟沙星及β-内酰胺类/β-内酰胺类酶抑制剂复合制剂等。结论头孢哌酮/舒巴坦对感染病原特别是MDR菌较其他抗生素有更好的抗菌活性,是临床感染治疗的较好选择。Objective To analyze the antimicrobial susceptibility of cefoperazone/sulbactam to bacteria especially the MDR bacteria isolated from clinical samples. Methods Antimicrobial susceptibility of cefoperazone/ sulbactam to bacteria isolated from clinical samples was determined by the disc diffusion method. The results were analyzed according to the CLSI standard of cefoperazone and compared with the resistance against other antibiotics. Results The drug resistant rate of cefoperazone/sulbactam to common Gram negative bacteria isolated from clinical samples （10.8%） was significantly lower than those of others antibiotics except imipenem and amikacin. The drug resistant rate of cefoperazone/sulbactam to Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacteriaceae producing extended spectrum beta lactamases, and carbapenem was 41.3%, 13.5%, 14%, and 59.3%, respectively, which were lower than that of the third generation cephalosporin, levofloxacin, and beta lactam/beta lactamase inhibitors. Conclusion Cefoperazone/sulbactam with better antimicrobial activity against infectious pathogens particularly the multi drug resistant bacteria is a good choice for the treatment of infectious diseases in clinical.

关 键 词：头孢哌酮/舒巴坦 临床分离菌 药物敏感性 

分 类 号：R978.1[医药卫生—药品]